"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 3 | 3 | 6 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 3 | 3 | 6 |
| 2009 | 1 | 3 | 4 |
| 2010 | 7 | 0 | 7 |
| 2011 | 3 | 0 | 3 |
| 2012 | 7 | 0 | 7 |
| 2013 | 4 | 2 | 6 |
| 2014 | 7 | 2 | 9 |
| 2015 | 5 | 1 | 6 |
| 2016 | 2 | 2 | 4 |
| 2017 | 2 | 3 | 5 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 4 | 6 |
| 2021 | 6 | 1 | 7 |
| 2022 | 1 | 3 | 4 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 Sep; 8:e2400258.
-
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. J Clin Oncol. 2024 Jul 20; 42(21):2537-2545.
-
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts. Cancer Res Commun. 2024 03 19; 4(3):834-848.
-
An updated definition of V(D)J recombination signal sequences revealed by high-throughput recombination assays. Nucleic Acids Res. 2022 Nov 11; 50(20):11696-11711.
-
ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. Cancer Lett. 2023 01 01; 552:215981.
-
Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta-analysis. J Neuroendocrinol. 2022 07; 34(7):e13149.
-
Cullin neddylation inhibitor attenuates hyperglycemia by enhancing hepatic insulin signaling through insulin receptor substrate stabilization. Proc Natl Acad Sci U S A. 2022 02 08; 119(6).
-
Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172.
-
Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1?. Proc Natl Acad Sci U S A. 2021 05 25; 118(21).
-
SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. Cancer Res. 2021 06 01; 81(11):3067-3078.